Patent Trial and Appeal Board Upholds the Validity of LIALDA® Patent

Lexington, Massachusetts (ots/PRNewswire) -

Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S.
Patent & Trademark Office's Patent Trial and Appeal Board (PTAB) has
issued their decision upholding the validity of U.S. Patent No.
6,773,720, related to Shire's LIALDA® (mesalamine) product.

The petition seeking to institute inter partes review (IPR) was
filed with the U.S. Patent and Trademark Office's Patent Trial and
Appeal Board (PTAB) in April of 2015 by the Coalition For Affordable
Drugs (CFAD) II L.L.C. Fund. The PTAB found that the patent was
valid in light of the challenges put forward by the petitioner.

Shire is pleased with the decision and will continue to vigorously
defend its patents to protect the innovation and value Shire products
bring to patients.

LIALDA remains the only once-daily mesalamine product indicated
for both the induction of remission of mild to moderate ulcerative
colitis and for the maintenance of remission of UC. There have not
been any approvals of generic versions of LIALDA.

Indication

Lialda is a prescription medication approved for the induction of
remission in patients with active, mild to moderate ulcerative
colitis (UC) and for the maintenance of remission of UC.

Important Safety Information

Do not take Lialda (mesalamine) if you are allergic to
salicylates, such as aspirin, or medications that contain aspirin;
aminosalicylates; mesalamine; or any other ingredients in Lialda.

Tell your doctor if you:

- have or have had kidney problems. Kidney problems have been
reported with medications that contain mesalamine, such as Lialda.
Your doctor may check to see how your kidneys are working before
starting Lialda and periodically while taking Lialda.
- have symptoms including cramping, stomach ache, bloody diarrhea,
fever, headache, and rash. Medications that contain mesalamine,
such as Lialda, have been associated with a condition that may be
hard to tell apart from a UC flare. Call your doctor right away if
you have any of these symptoms. He or she may tell you to stop
taking Lialda.
- are allergic to sulfasalazine, as you may also be allergic to
Lialda or medications that contain mesalamine.
- have or have had heart-related allergic reactions, such as
inflammation of the heart muscle (myocarditis) or the lining of the
heart (pericarditis). These reactions have been seen in patients
taking Lialda or medications that contain mesalamine. Your chance
of having these types of reactions may increase when taking Lialda.
- have or have had liver problems. Problems with liver function have
been reported in patients who have or have had liver problems and
were taking medications that contain mesalamine, such as Lialda.
- have a stomach blockage. It may take longer for Lialda to start
working.

The most common side effects reported in clinical studies of
Lialda were:

- ulcerative colitis
- headache
- passing gas
- abnormal liver function test results
- stomach ache

In clinical studies of Lialda, inflammation of the pancreas also
occurred. If this happens to you, your doctor may tell you to stop
taking Lialda.

Other side effects may occur.

Before starting Lialda, tell your doctor about all medications you
are taking, including:

- non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen
and naproxen. Taking these medications with Lialda may increase
your chance of kidney problems.
- azathioprine and 6-mercaptopurine. Taking these medications with
Lialda may increase your chance of blood disorders.

Please see Full Prescribing Information
(http://pi.shirecontent.com/?product=LIALDA&country=USA&language=ENG)
for Lialda (mesalamine)

You are encouraged to report negative side effects of prescription
drugs to the FDA.

Visit http://www.FDA.gov/medwatch, or call 1-800-FDA-1088.

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on
serving people with rare diseases and other highly specialized
conditions. We strive to develop best-in-class products, many of
which are available in more than 100 countries, across core
therapeutic areas including Hematology, Immunology, Neuroscience,
Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal
Medicine / Endocrine and Hereditary Angioedema; and a growing
franchise in Oncology.

Our employees come to work every day with a shared mission: to
develop and deliver breakthrough therapies for the hundreds of
millions of people in the world affected by rare diseases and other
high-need conditions, and who lack effective therapies to live their
lives to the fullest.

http://www.shire.com

Forward-Looking Statements

Statements included herein that are not historical facts,
including without limitation statements concerning future strategy,
plans, objectives, expectations and intentions, the anticipated
timing of clinical trials and approvals for, and the commercial
potential of, inline or pipeline products are forward-looking
statements. Such forward-looking statements involve a number of risks
and uncertainties and are subject to change at any time. In the event
such risks or uncertainties materialize, Shire's results could be
materially adversely affected. The risks and uncertainties include,
but are not limited to, the following:

- Shire's products may not be a commercial success;
- increased pricing pressures and limits on patient access as a
result of governmental regulations and market developments may
affect Shire's future revenues, financial condition and results of
operations;
- Shire conducts its own manufacturing operations for certain of its
products and is reliant on third party contract manufacturers to
manufacture other products and to provide goods and services. Some
of Shire's products or ingredients are only available from a single
approved source for manufacture. Any disruption to the supply
chain for any of Shire's products may result in Shire being unable
to continue marketing or developing a product or may result in
Shire being unable to do so on a commercially viable basis for some
period of time;
- the manufacture of Shire's products is subject to extensive
oversight by various regulatory agencies. Regulatory approvals or
interventions associated with changes to manufacturing sites,
ingredients or manufacturing processes could lead to significant
delays, an increase in operating costs, lost product sales, an
interruption of research activities or the delay of new product
launches;
- certain of Shire's therapies involve lengthy and complex processes,
which may prevent Shire from timely responding to market forces and
effectively managing its production capacity;
- Shire has a portfolio of products in various stages of research and
development. The successful development of these products is highly
uncertain and requires significant expenditures and time, and there
is no guarantee that these products will receive regulatory
approval;
- the actions of certain customers could affect Shire's ability to
sell or market products profitably. Fluctuations in buying or
distribution patterns by such customers can adversely affect
Shire's revenues, financial conditions or results of operations;
- Shire's products and product candidates face substantial
competition in the product markets in which it operates, including
competition from generics;
- adverse outcomes in legal matters, tax audits and other disputes,
including Shire's ability to enforce and defend patents and other
intellectual property rights required for its business, could have
a material adverse effect on the combined company's revenues,
financial condition or results of operations;
- inability to successfully compete for highly qualified personnel
from other companies and organizations;
- failure to achieve the strategic objectives with respect to Shire's
acquisition of NPS Pharmaceuticals, Inc., Dyax Corp. ("Dyax") or
Baxalta Inc. ("Baxalta")may adversely affect Shire's financial
condition and results of operations;
- Shire's growth strategy depends in part upon its ability to expand
its product portfolio through external collaborations, which, if
unsuccessful, may adversely affect the development and sale of its
products;
- a slowdown of global economic growth, or economic instability of
countries in which Shire does business, as well as changes in
foreign currency exchange rates and interest rates, that adversely
impact the availability and cost of credit and customer purchasing
and payment patterns, including the collectability of customer
accounts receivable;
- failure of a marketed product to work effectively or if such a
product is the cause of adverse side effects could result in damage
to the Shire's reputation, the withdrawal of the product and legal
action against Shire;
- investigations or enforcement action by regulatory authorities or
law enforcement agencies relating to Shire's activities in the
highly regulated markets in which it operates may result in
significant legal costs and the payment of substantial compensation
or fines;
- Shire is dependent on information technology and its systems and
infrastructure face certain risks, including from service
disruptions, the loss of sensitive or confidential information,
cyber-attacks and other security breaches or data leakages that
could have a material adverse effect on Shire's revenues, financial
condition or results of operations;
- Shire incurred substantial additional indebtedness to finance the
Baxalta acquisition, which may decrease its business flexibility
and increase borrowing costs;
- difficulties in integrating Dyax or Baxalta into Shire may lead to
the combined company not being able to realize the expected
operating efficiencies, cost savings, revenue enhancements,
synergies or other benefits at the time anticipated or at all; and

other risks and uncertainties detailed from time to time in
Shire's filings with the Securities and Exchange Commission,
including those risks outlined in "ITEM 1A: Risk Factors" in Shire's
Quarterly Report on Form 10-Q for the quarter ended June 30, 2016.

All forward-looking statements attributable to us or any person
acting on our behalf are expressly qualified in their entirety by
this cautionary statement. Readers are cautioned not to place undue
reliance on these forward-looking statements that speak only as of
the date hereof. Except to the extent otherwise required by
applicable law, we do not undertake any obligation to update or
revise forward-looking statements, whether as a result of new
information, future events or otherwise.

ots Originaltext: Shire Pharmaceuticals Group Plc
Im Internet recherchierbar: http://www.presseportal.de

Contact:
please contact:
Investor Relations
Sarah Elton-Farr
seltonfarr@shire.com
+44-1256-894157

Ian Karp
ikarp@shire.com
+1-781-482-9018

Robert Coates
rcoates@shire.com
+44-1256-894874

Media
Gwen Fisher
gfisher@shire.com
+1-484-595-9836

Debbi Ford
debbi.ford@shire.com
+1-617-949-9083

Original-Content von: Shire Pharmaceuticals Group Plc, übermittelt durch news aktuell